Home / Health / US medication drug spending rose 13 pct in 2014-IMS report

US medication drug spending rose 13 pct in 2014-IMS report


April 14 (Reuters) – U.S. spending on medication medicines
jumped 13 percent to $374 billion in 2014, a biggest
percentage boost given 2001, as direct surged for expensive
new breakthrough hepatitis C treatments, a news expelled on
Tuesday showed.

Demand for newer cancer and mixed sclerosis treatments,
price increases on branded medicines, quite insulin
products for diabetes, and a entrance of few new general versions
of big-selling drugs also contributed to a double-digit
spending arise in 2014, a news by IMS Health Holdings Inc
found.

IMS, a U.S. health caring information and record company,
does not predict a identical U.S. spending burst on prescription
medicines this year.

“We positively design to see expansion in a marketplace distance and
spending turn in 2015, though not during a rate of expansion that we’re
reporting for 2014,” pronounced Murray Aitken, executive executive of
the IMS Institute for Healthcare Informatics, that gathered the
report.

“We know that a obvious expiry impact will be incomparable in
2015 than it was final year,” he said.

New hepatitis C treatments from Gilead Sciences Inc
that probably pledge a heal for a liver-destroying virus,
with few side effects, led some-more than 161,000 patients to start
treatment in 2014, IMS said. That compares to usually 17,000 in
2013, when thousands put off diagnosis while watchful for a new
drugs.

Gilead reported a record-breaking $10.3 billion in
first-year sales of Sovaldi as a $1,000-a-pill drug became the
poster child for heated critique of a high cost of new
medicines.

The news also remarkable a vast series of supposed orphan
drugs that done it to a marketplace in 2014, with a introduction
of 18 costly medicines for singular diseases.

Meanwhile, a entrance of new general versions of branded
drugs reduced spending by usually about $12 billion in 2014,
compared to an impact of about $20 billion a year before and
$29 billion in assets in 2012, when inexpensive general versions of
Pfizer Inc’s top-selling cholesterol drug Lipitor began
to inundate a market.

The obtuse assets from general drugs in 2014 was due in
part to U.S. Food and Drug Administration sanctions against
India’s Ranbaxy that behind inexpensive versions of AstraZeneca Plc’s
blockbuster heartburn drug Nexium.

IMS, that compiles U.S. medication drug information for the
industry, also tracked a impact of a Affordable Care Act on
medicine usage, observant a poignant arise in prescriptions
filled by supervision Medicaid programs. While those rose by
about 17 percent overall, a boost was 25 percent in a 28
states that stretched Medicaid eligibility underneath ACA.

(Reporting by Bill Berkrot; Editing by Richard Chang)

Article source: http://in.reuters.com/article/2015/04/14/health-spending-medicine-idINL2N0X52EH20150414

Scroll To Top